The KLOW peptide blend is an 80 mg research blend labeled 50 mg GHK-Cu, 10 mg BPC-157, 10 mg TB-500 and 10 mg KPV per vial. KLOW is the GLOW stack plus KPV. It is supplied for in vitro laboratory research only and is not approved by the FDA for human or veterinary use. Sourced against a ≥99% HPLC purity specification, with a lot-matched third-party CoA where on file.
BPC-157 and TB-500 act at different points of the tissue-repair cascade, which is why they are studied together rather than treated as interchangeable. BPC-157 (15 residues, GEPPPGKPADDAGLV, C62H98N16O22, 1,419.5 Da, CAS 137525-51-0) upregulates VEGF and activates focal adhesion kinase and paxillin where it is introduced. TB-500 (synthetic Thymosin β-4, C212H350N56O78S, 4,963.4 Da, CAS 77591-33-4, carrying the LKKTET actin-binding motif at residues 17–22) sequesters monomeric G-actin, releasing the cytoskeletal brake on cell migration. That sequential reading is a mechanistic inference drawn from two separate single-compound literatures — no published study has run the two compounds together and measured the result, and both are supplied for in-vitro laboratory research only.
Evaluating a research peptide supplier comes down to four documents and one question each. HPLC purity tells you what proportion of the material is the target peptide by area under the curve — it does not tell you what the remainder is. LC-MS/MS tells you the molecular identity, which is the only reliable way to know that the powder in the vial is the molecule on the label. LAL endotoxin testing measures bacterial endotoxin load, not sterility. And a batch-specific Certificate of Analysis ties all three to the lot number printed on the vial, which is what makes a result reproducible. Most compounds sold on this market are not FDA-approved for human use, several are WADA-prohibited, and research-market material is not manufactured under pharmaceutical GMP.